AstraZeneca PLC (AZN) Stock Forecast
AZN analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.25 / 5 from 12 analysts
- Price target
- $207.16 average of analyst targets
- Upside to target
- +25.2% from the latest close
- Next earnings
- October 30, 2026 EPS estimate $2.16
- 52-week range
- $155.62 – $209.48
AZN analyst ratings
12 analystsNumber of analysts at each rating.
AZN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AZN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.15 | $1.15 | $1.15 | — | — | 1 |
| Current fiscal year (2026) | $10.05 | $10.00 | $10.11 | $4.58 | +119.4% | 3 |
| Next fiscal year (2027) | $11.34 | $10.84 | $11.84 | $10.05 | +12.9% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AZN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $15.99B | $15.78B | $16.25B | +5.3% | 10 |
| Current fiscal year (2026) | $63.40B | $62.56B | $64.35B | +7.9% | 25 |
| Next fiscal year (2027) | $67.37B | $64.51B | $69.43B | +6.3% | 25 |
AZN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AZN revenue: reported and forecast
AZN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.17 | $0.00 | $0.00 | $0.00 | $1.15 | −1.8% | 0 up · 0 down |
| Current fiscal year (2026) | $8.13 | $10.09 | $10.05 | $10.07 | $10.05 | +23.6% | 0 up · 1 down |
| Next fiscal year (2027) | $9.27 | $11.58 | $11.36 | $11.56 | $11.34 | +22.4% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AZN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; AZN beat in 10 of 12.
What analysts expect from AZN
12 analysts cover AstraZeneca; their consensus rating is buy (4.25 on a 1–5 scale, where 5 is a strong buy). The average price target is $207.16, 25.2% above the latest close of $165.41. Analysts expect earnings of $10.05 per share for 2026, +119.4% from a year earlier. For 2027 the average estimate is $11.34 per share on revenue of $67.4 billion. AstraZeneca beat the EPS estimate in 10 of the last 12 quarters.
Related: AZN income statement, AZN key metrics, AZN chart. See the AZN stock overview for the latest quote and news.
AZN forecast FAQ
What is AstraZeneca's price target?
The average analyst price target for AstraZeneca is $207.16, 25.2% above the latest close of $165.41.
Is AstraZeneca a buy, hold or sell?
Of 12 analysts covering AstraZeneca, 7 rate it a strong buy, 3 a buy, 1 a hold, 0 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is AstraZeneca's EPS forecast?
Analysts forecast $10.05 per share for 2026 (range $10.00 to $10.11); for 2027 the estimate is $11.34.
What is AstraZeneca's revenue forecast?
The average revenue estimate for 2026 is $63.4 billion, growth of 7.9%; for 2027 it is $67.4 billion.
When does AstraZeneca report earnings?
AstraZeneca is expected to report results for the quarter ending September 30, 2026 on October 30, 2026 before the market opens; the EPS estimate is $2.16.
Does AstraZeneca usually beat earnings estimates?
AstraZeneca reported EPS at or above the analyst estimate in 10 of the last 12 quarters.